Article Dans Une Revue Drugs - Real World Outcomes Année : 2025

Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Yoram Bouhnik
Carine Salliot
Ben Braithwaite
Salima Hateb
  • Fonction : Auteur
Janet Addison
  • Fonction : Auteur

Dates et versions

hal-04910071 , version 1 (24-01-2025)

Identifiants

Citer

Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, et al.. Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Drugs - Real World Outcomes, 2025, ⟨10.1007/s40801-024-00477-4⟩. ⟨hal-04910071⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More